Oppenheimer Maintains Outperform on ESSA Pharma, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on ESSA Pharma (NASDAQ:EPIX) with a $17 price target.
May 16, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Leland Gershell has reiterated an Outperform rating for ESSA Pharma (NASDAQ:EPIX) and maintained a price target of $17.
The reaffirmation of an Outperform rating and a $17 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100